Summary
Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript
Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript
Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago.
Delcath: Fundamentals Intact, Despite Share Price Weakness
Delcath Systems, Inc.'s revenue remains under pressure due to weak patient starts in the third quarter of 2025. The fundamentals of the company remain intact, though, and 2026 should be another year of strong growth. Delcath's profitability will be under pressure due to investments in clinical trials and sales and marketing.
Delcath Systems Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 SkyOak Wealth SkyOak Wealth LLC | 15,000 | $151,500 | $194,700 | $43,200 | 28.51% |
 Joseph Castro Nuveen LLC | 103,774 | $1.25M | $1.36M | $107,674.43 | 8.62% |
| SE Sima Elimelech Activest Wealth Management | 1,000 | $8,370 | $13,180 | $4,810 | 57.47% |
 Jennifer Grunberg Allspring Global Investments Holdings LLC | 32,081 | $297,711.68 | $421,618.13 | $123,906.45 | 41.62% |
 Bobby Adusumilli SJS Investment Consulting Inc. | 3 | $27.84 | $39.43 | $11.59 | 41.63% |
Delcath Systems Inc. (DCTH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Delcath Systems Inc. ever had a stock split?
Delcath Systems Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Gerard J. Michel CEO | NASDAQ (CM) Exchange | 24661P807 CUSIP |
| US Country | 156 Employees | - Last Dividend | 24 Dec 2019 Last Split | - IPO Date |
Overview
Delcath Systems, Inc. is an interventional oncology company dedicated to the treatment of primary and metastatic liver cancers primarily within the United States and Europe. Since its incorporation in 1988, the company has been focused on developing innovative treatments that aim to improve the quality of life for patients afflicted with liver cancer. With its headquarters located in New York, New York, Delcath Systems, Inc. has been at the forefront of delivering targeted therapies for liver cancer patients, striving to limit systemic exposure and reduce the side effects commonly associated with high-dose chemotherapy treatments.
Products and Services
- HEPZATO KIT
This lead product candidate from Delcath Systems, Inc. is a combination of melphalan for injection and a hepatic delivery system designed to administer high-dose chemotherapy directly to the liver, thereby controlling systemic exposure and minimizing associated side effects. It embodies the company's dedication to interventional oncology by offering a targeted treatment approach for liver cancer patients.
- FOCUS Clinical Trial
As part of its clinical development program for HEPZATO, the FOCUS clinical trial represents Delcath's commitment to advancing the treatment of metastatic hepatic dominant Uveal Melanoma. This trial aims to investigate the objective response rate in patients with metastatic uveal melanoma, underscoring the company’s focus on addressing this challenging cancer subtype through innovative treatment methodologies.
- CHEMOSAT Hepatic Delivery System for Melphalan/CHEMOSAT
In Europe, Delcath provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan, or simply CHEMOSAT. This allows medical centers across Europe to treat a variety of liver cancers with a system that is designed to deliver high-dose chemotherapy directly to the liver, targeting cancer cells more effectively while sparing the rest of the body from the harsh effects of chemotherapy.
